Overview

A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function

Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.
Phase:
PHASE1
Details
Lead Sponsor:
Shandong Suncadia Medicine Co., Ltd.